Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radiancy psoriasis therapy:

This article was originally published in Clinica

Executive Summary

The US FDA has given Radiancy 510(k) clearance to market its phototherapy for psoriasis, which is based on its proprietary Light Heat Energy technology. The psoriasis light unit assembly (LUA) has been shown in clinical studies to be a safe and effective treatment for mild to moderate plaque and guttate psoriases, said the Orangeburg, New York firm; patients in the study showed an average reduction of 65% on the Psoriasis Severity Index (PSI). Radiancy said that LHE-based phototherapy systems were already cleared in the US for removing hair and treating acne vulgaris and pigmented and vascular lesions on all skin types and that the modular psoriasis LUA could be attached quickly to the systems.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel